Associated Papers
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients.
Li W et al.
Cancers, 2025
Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients.
Jha P et al.
Clinical Lung Cancer, 2024
Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
Gou Q et al.
Scientific Reports, 2024
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome.
Diaz-Jimenez A et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2024
The rapidly changing field of predictive biomarkers of non-small cell lung cancer.
Tóth LJ et al.
Pathology Oncology Research : Por, 2024
EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M et al.
Molecular Oncology, 2023
Identification of prognostic factors in classic Hodgkin lymphoma by integrating whole slide imaging and next generation sequencing.
Santisteban-Espejo A et al.
Molecular Omics, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E et al.
Molecular Oncology, 2021
Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation.
Patil K et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.
Fois SS et al.
International Journal of Molecular Sciences, 2021
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics.
Chan HT et al.
Oncology and Therapy, 2019
Resistance to molecularly targeted therapy in non-small-cell lung cancer.
Asao T et al.
Respiratory Investigation, 2019
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Testa U et al.
Cancers, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman NI et al.
Archives of Pathology & Laboratory Medicine, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman NI et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
Lindeman NI et al.
The Journal of Molecular Diagnostics : Jmd, 2018
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.
Salgia R
Expert Review of Molecular Diagnostics, 2016
Challenges and opportunities for next-generation sequencing in companion diagnostics.
Lin E et al.
Expert Review of Molecular Diagnostics, 2015
Going beyond EGFR.
Zimmermann S et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2012